Trulieve Cannabis Corp. (NYSE:TRLV – Get Free Report)’s stock price traded down 5% on Friday . The stock traded as low as $11.42 and last traded at $11.07. Approximately 121,247 shares traded hands during trading, a decline of 84% from the average session volume of 764,057 shares. The stock had previously closed at $11.65.
Wall Street Analysts Forecast Growth
Several research firms have recently weighed in on TRLV. Wall Street Zen downgraded shares of Trulieve Cannabis from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Trulieve Cannabis in a research note on Friday, September 11th. Cantor Fitzgerald reiterated an “overweight” rating and set a $15.00 price objective on shares of Trulieve Cannabis in a research report on Friday, August 7th. Finally, Zacks Research raised shares of Trulieve Cannabis to a “hold” rating in a research note on Thursday, June 18th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Trulieve Cannabis has an average rating of “Hold” and a consensus target price of $15.00.
View Our Latest Stock Report on TRLV
Trulieve Cannabis Stock Down 6.1%
Trulieve Cannabis (NYSE:TRLV – Get Free Report) last posted its earnings results on Friday, August 7th. The company reported $0.11 EPS for the quarter, topping the consensus estimate of $0.06 by $0.05. The business had revenue of $271.00 million during the quarter, compared to the consensus estimate of $268.82 million. Equities research analysts expect that Trulieve Cannabis Corp. will post 0.31 EPS for the current year.
Insider Buying and Selling at Trulieve Cannabis
In other news, CEO Kim Rivers sold 136,811 shares of the company’s stock in a transaction dated Friday, June 26th. The stock was sold at an average price of $8.76, for a total transaction of $1,198,464.36. Following the completion of the sale, the chief executive officer owned 1,476,913 shares in the company, valued at approximately $12,937,757.88. This represents a 8.48% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 1,421,626 shares of company stock valued at $12,051,085 over the last ninety days. 3.79% of the stock is owned by insiders.
About Trulieve Cannabis
Trulieve Cannabis Corp. is a vertically integrated cannabis company that cultivates, processes, manufactures and sells medical and adult-use cannabis products. Its product portfolio includes flower, pre-rolls, concentrates, edibles, tinctures, capsules and topical products, marketed under the Trulieve brand and other affiliated brands.
The company sells its products through a network of company-operated dispensaries and, where permitted, through wholesale and other distribution channels.
Featured Articles
- Five stocks we like better than Trulieve Cannabis
- 2 Stocks Breaking Out Post-FOMC With One Thing in Common
- Lennar’s Q3 Miss Hides a Stronger Operating Story Beneath the Housing Slump
- These 3 Stocks Are Drawing Insider Buyers for Very Different Reasons
- Braze Beat Expectations—Now 2 SaaS Peers Are in Focus
Receive News & Ratings for Trulieve Cannabis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trulieve Cannabis and related companies with MarketBeat.com's FREE daily email newsletter.
